Loading
Adding relacorilant, a drug that blocks the cortisol receptor and thereby restores chemotherapy sensitivity, to nab-paclitaxel lengthened progression-free and overall survival in platinum-resistant ovarian cancer regardless of any biomarker.
Phase 3 trial of 381 patients with platinum-resistant ovarian cancer and one to three prior lines randomised to intermittent relacorilant plus nab-paclitaxel or nab-paclitaxel alone.
Median progression-free survival was 6.54 versus 5.52 months (hazard ratio 0.70) and interim median overall survival 15.97 versus 11.50 months (hazard ratio 0.69), with a similar safety profile between arms.
Relacorilant with nab-paclitaxel is a new option for platinum-resistant disease that does not depend on folate receptor status, with regulatory review following the trial.
Shares ROSELLA / GOG-3073, Relacorilant.